Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 393.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 31 March 2026' and includes detailed operational updates, clinical trial progress, research and development activities, corporate activities, and financial commentary including cash flow and expenditure for the quarter. It references the Appendix 4C Quarterly Cash Flow Report, which is a standard quarterly report for Australian listed companies. The content is comprehensive and substantive, covering a period shorter than a full fiscal year (quarterly). It contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-28 English
Notification of cessation of securities - NTI 4 pages 14.8KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 3H form titled “Notification of cessation of securities,” detailing the expiry and cessation of unquoted options and the resulting change in issued capital. This is a corporate capital structure change rather than an earnings, management appointment, or regulatory announcement. It fits the definition of a share issue/capital change event. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2026-04-27 English
Change of Director's Interest Notice 2 pages 282.6KB
Director's Dealing Classification · 90% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” detailing a director’s disposal of unlisted options and updated shareholdings under ASX Listing Rule 3.19A.2. This is a report of personal transactions by a company director (insider dealing). The appropriate category is Director’s Dealing (DIRS).
2026-04-27 English
Ceasing to be a substantial holder 3 pages 519.3KB
Major Shareholding Notification Classification · 98% confidence The document is ASIC Form 605 “Notice of ceasing to be a substantial holder” under the Corporations Act 2001. It reports changes in substantial shareholdings (i.e. relevant interests crossing thresholds) by Maybank Securities Pte. Ltd. This matches the definition of a Major Shareholding Notification (MRQ).
2026-04-22 English
Neurotech to present at Ignite Investment Summit Hong Kong 14 pages 3.9MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 13 April 2026, detailing Neurotech International Limited's participation in the Ignite Investment Summit in Hong Kong. It includes a presentation by the CEO about the company's clinical-stage biopharmaceutical developments, specifically the NTI164 therapy for neurodevelopmental disorders. The text contains detailed information about the company's clinical trials, pipeline, market opportunity, and future plans. The document is approximately 15,000 characters long and includes a full presentation with data, clinical trial phases, and strategic outlook. This is a detailed investor presentation focusing on financials, strategy, and market position rather than a brief announcement or regulatory filing. It is not an earnings release, annual report, or interim report, nor is it a simple announcement of a report publication. Therefore, the most appropriate classification is Investor Presentation (IP).
2026-04-12 English
Change of Director's Interest Notice x 4 8 pages 1.1MB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after the change, dates of changes, and nature of the changes. The document is a formal notification of personal share transactions by company directors. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2026-03-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.